Purpose: To compare the efficacy and safety of five single-target glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adults with overweight or obesity and explore whether trial-level physical activity (PA)/lifestyle support modified treatment effects.Methods: We searched PubMed, Embase, Web of Science, Cochrane Library, and Scopus from inception to April 2026 for randomized controlled trials evaluating liraglutide, semaglutide, exenatide, dulaglutide, or lixisenatide (≥4 weeks). Bayesian random-effects network meta-analyses assessed weight-related outcomes, HbA1c, and safety outcomes. Exploratory analyses examined the effects of PA/lifestyle support and dose. This review was registered in PROSPERO (CRD420261389913).Results: Ninety-six trials involving 220 treatment arms were included. Semaglutide showed the greatest estimated reductions in body weight (MD −12.71 kg, 95% CrI −16.43 to −9.05), HbA1c (MD −1.33%, 95% CrI −2.42 to −0.29), percentage weight change (MD −14.79%, 95% CrI −19.31 to −10.18), and waist circumference (MD −11.99 cm, 95% CrI −15.77 to −8.19), although certainty of evidence for efficacy outcomes was very low. PA/lifestyle support was associated with additional weight reduction (MD −2.08 kg, 95% CrI −3.63 to −0.54) in one comparison, while other effects were uncertain. Semaglutide increased risks of treatment discontinuation due to adverse events, nausea, and vomiting, but not serious adverse events.Conclusion: Among five single-target GLP-1RAs, semaglutide demonstrated the greatest estimated efficacy but higher gastrointestinal intolerance. Trial-level PA/lifestyle support may contribute to heterogeneity in weight outcomes, whereas no consistent dose-related pattern was observed. Treatment selection should consider efficacy, tolerability, patient characteristics, and evidence certainty.